ImmunityBio (IBRX)
Commercializes ANKTIVA while developing cytokine, NK-cell, and vaccine immunotherapies for cancer.
$8.85
vs last close−0.45 (−4.79%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
in 41 days
EPS estimate
−$0.08
Revenue estimate
$59.2M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.09−$0.15−$0.10−$0.07−$0.06−$0.62−$0.22Pending
Estimate−$0.26−$0.12−$0.10−$0.10−$0.08−$0.08−$0.08−$0.08
Surprise+65.4%−25.0%0.0%+30.0%+25.0%−675.0%−175.0%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$7.6M$16.5M$26.4M$32.1M$38.3M$44.2M$51.2MPending
Estimate$9.6M$16.6M$31.9M$37.8M$38.4M$43.1M$49.7M$59.2M
Surprise−21.5%−0.5%−17.1%−15.1%−0.2%+2.6%+3.1%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.13 | — | — |
| Sep 2028 | $0.13 | — | — |
| Jun 2028 | $0.14 | — | — |
| Mar 2028 | $0.11 | — | — |
| Dec 2027 | −$0.08 | — | — |
| Sep 2027 | −$0.09 | — | — |
| Jun 2027 | −$0.09 | — | — |
| Mar 2027 | −$0.09 | — | — |
| Dec 2026 | −$0.07 | — | — |
| Nov 2026 | −$0.08 | — | — |
| Aug 2026 | −$0.08 | −$0.22 | −175.0% |
| May 2026 | −$0.08 | −$0.62 | −675.0% |
| Feb 2026 | −$0.08 | −$0.06 | +25.0% |
| Nov 2025 | −$0.10 | −$0.07 | +30.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Sep 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.13 | — | — | $352.1M | — | — | — |
| Sep 2028 | $0.13 | — | — | $338.6M | — | — | — |
| Jun 2028 | $0.14 | — | — | $338.6M | — | — | — |
| Mar 2028 | $0.11 | — | — | $325.0M | — | — | — |
| Dec 2027 | −$0.08 | — | — | $90.1M | — | — | — |
| Sep 2027 | −$0.09 | — | — | $76.3M | — | — | — |
| Jun 2027 | −$0.09 | — | — | $71.0M | — | — | — |
| Mar 2027 | −$0.09 | — | — | $65.8M | — | — | — |
| Dec 2026 | −$0.07 | — | — | $71.2M | — | — | — |
| Nov 3, 2026 | −$0.08 | — | — | $59.2M | — | — | — |
| Aug 4, 2026 | −$0.08 | −$0.22 | −175.0% | $49.7M | $51.2M | +3.1% | −2.8% |
| May 7, 2026 | −$0.08 | −$0.62 | −675.0% | $43.1M | $44.2M | +2.6% | −7.4% |
| Feb 23, 2026 | −$0.08 | −$0.06 | +25.0% | $38.4M | $38.3M | −0.2% | +13.0% |
| Nov 4, 2025 | −$0.10 | −$0.07 | +30.0% | $37.8M | $32.1M | −15.1% | −8.0% |
| Aug 5, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 3, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 12, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 19, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 1, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 2, 2022 | |||||||
| Dec 30, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 14, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 7, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 25, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 8, 2019 | |||||||
| Mar 13, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 6, 2018 | |||||||
| May 7, 2018 | |||||||
| Mar 12, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 15, 2017 | |||||||
| Nov 10, 2016 | |||||||
| Aug 15, 2016 | |||||||
| May 16, 2016 | |||||||
| Mar 30, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Sep 10, 2015 |